Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Mr. Samraat Raha 2023 'den beri şirketle birlikte olan Myriad Genetics Inc 'in President 'ıdır.
MYGN hissesinin fiyat performansı nasıl?
MYGN 'in mevcut fiyatı $4.84 'dir, son işlem günde 1.25% arttırılmış etti.
Myriad Genetics Inc için ana iş temaları veya sektörler nelerdir?
Myriad Genetics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Myriad Genetics Inc 'in piyasa değerlemesi nedir?
Myriad Genetics Inc 'in mevcut piyasa değerlemesi $451.1M 'dir
Myriad Genetics Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 13 analist Myriad Genetics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 3 al, 10 tut, 4 sat ve 0 güçlü sat içermektedir